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Abstract 
Aim: Astrocytes are the main sources of extracellular ATP (eATP) within the 
brain, which functions as a gliotransmitter, capable of modulating neuronal and 
astrocytic activity. These cells play an important role in regulating energy 
homeostasis partly via astrocyte-derived ATP.  Given the role of AMPK in 
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regulating intracellular ATP levels, we hypothesised that AMPK may alter ATP 
release from astrocytes. 
Methods: Measurements of ATP release were made from human U373 
astrocytoma cells, primary mouse hypothalamic (HTAS) and cortical astrocytes 
(CRTAS) and wild type and AMPK α1/α2 null mouse embryonic fibroblasts 
(MEFs). Cells were treated with drugs known to modulate AMPK activity: A-
769662, AICAR and metformin, for up to 3 hours. Intracellular calcium was 
measured using Fluo4 and Fura-2 calcium-sensitive fluorescent dyes.  
Results: In U373 cells, A-769662 (100 μM) increased AMPK phosphorylation, 
whereas AICAR and metformin (1 mM) induced a modest increase or had no 
effect, respectively. Only A-769662 increased extracellular ATP (eATP) levels, 
which was partially blocked by AMPK inhibitor Compound C. A-769662-induced 
increases in eATP were preserved in AMPK α1/α2 null MEF cells. A-769662 
increased intracellular calcium in U373, HTAS and CRTAS cells and chelation of 
intracellular calcium using BAPTA-AM reduced A-769662-induced eATP levels.  
A-769662 also increased ATP release from a number of other central and 
peripheral endocrine cell types. 
Conclusions: AMPK is required to maintain basal eATP levels but is not required 
for A-769662-induced increases in eATP. A-769662 (>50 μM) enhanced 
intracellular calcium levels leading to ATP release in an AMPK and purinergic 
receptor independent pathway.  
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Introduction: 
AMP-activated protein kinase (AMPK) is a cellular and whole body energy sensor 
involved in the regulation of energy homeostasis (for recent review see1). 
Structurally, AMPK is a heterotrimer composed of α, β and ϒ-subunits. The α-
subunit, which has two isoforms AMPKα1 and α2, contains the catalytic domain 
required for kinase activity.  The regulatory β- and ϒ-subunits subunits have two 
and three isoforms, respectively, with one isoform of each required as a scaffold 
for binding the catalytic domain of the kinase. Once active, AMPK switches off 
energy consuming pathways such as fatty acid synthesis, by phosphorylating and 
inhibiting acetyl CoA carboxylase (ACC)2, and protein translation via inhibition of 
the mammalian target of rapamycin (mTOR) pathway3. AMPK also stimulates 
energy production, for example by increasing glucose uptake4, with the net effect 
of maintaining intracellular ATP levels. 
 
Within the brain, AMPK is an important regulator of whole body glucose and 
energy homeostasis. Enhancement of AMPK activity in the arcuate nucleus 
increases food intake in mice and AMPK forms part of the signaling pathway by 
which leptin inhibits food intake5. Conversely, orexigenic hormones such as 
ghrelin require AMPK to stimulate food intake6. AMPK also plays a central role in 
glucose homeostasis as pharmacological activation of the kinase using AICAR can 
augment the counterregulatory response to insulin-induced hypoglycaemia in 
rats7.  
 
To date most research on the role of AMPK in the central nervous system (CNS) 
has focused on neurons; however, glial cells such as oligodendrocytes, microglia 
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and astrocytes also contain AMPK, yet little is currently known about its function 
within these cells.  Astrocytes play important supporting roles for neurons partly 
through releasing gliotransmitters into the extracellular space, such as ATP (for 
review see 8). In the brain, enhanced extracellular ATP (eATP) levels are widely 
accepted as a ubiquitous stress signal8, for example capable of initiating 
inflammatory signalling cascades by activating purinergic receptors (P2R)9.  
Several pieces of data suggest a potential role for glial-derived eATP in the 
regulation of whole body energy/glucose homeostasis that could be modulated 
by glial AMPK. Firstly, obesity is associated with glial cell activation in mice10-12 
and humans13 and recent data suggests that glia play a role in regulating feeding 
behaviour14-17. Astrocyte-derived eATP is broken down within the extracellular 
space to adenosine, which, via activation of the adenosine A1 receptor, inhibits 
the activity of hypothalamic agouti-related (AgRP) protein neurons, which are 
critical for the regulation of food intake18. This provides evidence for ATP, acting 
as a gliotransmitter, to modulate energy homeostasis. Moreover, microglia can 
be activated by eATP leading to initiation of the NF-κB signalling cascade and 
production of pro-inflammatory cytokines9, with NF-κB signalling in neurons 
and glia playing an important role in the regulation of energy homeostasis19, 20. 
Pro-inflammatory cytokine signalling is directly involved in the central control of 
energy homeostasis as intracerebroventricular injection of TNFα acutely inhibits 
food intake in rats21. Extracellular ATP is also neuromodulatory via activation of 
Ca2+-permeable P2X receptors and has been shown to excite hypothalamic 
steroidogenic factor 1 (SF-1) neurons, which are involved in the regulation of 
food intake22. 
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Given the importance of eATP in regulating myriad processes within the brain 
and the role of AMPK in regulating intracellular ATP levels, we hypothesized that 
AMPK may regulate eATP levels by blocking or reducing ATP release from 
astrocytes, thus maintaining intracellular ATP for metabolism. We tested this 
hypothesis in vitro by examining ATP release from human U373 astrocytoma 
cells and mouse primary hypothalamic and cortical astrocytes using the 
structurally distinct activators of AMPK, A-769662, AICAR and metformin. We 
conclude that only A-769662 alters eATP levels, which is mediated by increased 
release of calcium from intracellular stores, in a cell autonomous manner. 
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Materials and Methods 
Chemicals 
A-769662, AICAR and metformin were purchased from Tocris (Bristol, UK). A-
769662 was dissolved in DMSO (applied at a maximum volume:volume ratio of 
0.1%). AICAR and metformin were dissolved in water. 
 
Cell culture 
U373 cells were purchased from Public Health England. Primary mouse 
astrocytes were isolated from neonatal mice P1-5 and validated as astrocyte-
enriched cultures of >80% GFAP-positive cells. Cultures contained less than 2% 
Iba1-positive microglial cells (ESM Figure 1). Wild type (WT) and AMPKα1/α2 
null MEF cells were a kind gift from Dr Benoit Viollet. All cell cultures were 
grown in stock media (DMEM, Sigma, UK) supplemented with 10% Hyclone FBS 
(ThermoFisher, UK) containing 25 mM glucose. Cells were seeded the day prior 
to experimentation and grown in media containing 7.5 mM glucose (sufficient to 
prevent glucose depletion overnight), supplemented with 10% FBS, with the 
exception of MEF cells, which were maintained in 25 mM glucose containing 
media. On the day of experimentation, cells were cultured in serum-free media 
(Gibco, UK) containing 2.5 mM glucose, a physiologically-relevant brain glucose 
concentration, for 2 hours before treatment (up to 3 hours).  
 
Immunoblotting 
Cells were grown to 60-70% confluence in 60 mm dishes. Protein was isolated 
using lysis buffer, protein concentrations determined by the method of Bradford 
and lysates subjected to SDS-PAGE and electrotransferred to nitrocellulose 
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membrane. Proteins (total and phosphorylated) were immunoblotted and 
identified using infrared fluorescence using the Licor Odyssey scanner (see 
supplementary methods for antibody details).  
 
Determination of ATP concentrations 
Extracellular and intracellular ATP levels were determined using ATPLite two-
step (PerkinElmer, UK) as per the manufacturer’s instructions, with minor 
modifications (see supplementary methods).  
 
Calcium imaging 
Intracellular calcium was measured using either Fluo4 Direct (ThermoFisher, 
UK) using a Pherastar FS plate reader or Fura-2 (Life Technologies, UK) for 
single cell calcium imaging (see supplementary methods). 
 
Assessment of cellular metabolism 
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of 
U373 cells was assessed using a Seahorse Bioscience XFe96 extracellular flux 
analyser (see supplementary methods for assay conditions).  
 
Statistical analysis 
A one-sample t-test was used to determine significant changes in 
phosphorylation, relative to control. For comparisons of two groups an unpaired 
t-test was used and for multiple group comparisons, a one-way ANOVA with 
post-hoc Bonferroni were used. Statistical tests performed using GraphPad 
Prism software (Prism 5; GraphPad Software, La Jolla, CA, USA). Results are 
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expressed as mean ± standard error, unless otherwise stated. p values of <0.05 
were considered statistically significant. 
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Results 
A-769662 potently activates AMPK and stimulates ATP release from human U373 
astrocytoma cells 
U373 astrocytoma cells were treated for 30 minutes (Fig. 1A-D) or 3 hours (Fig. 
1E-H) with compounds reported to activate AMPK: A-769662 (100 μM), AICAR 
(1 mM) or metformin (1 mM). A-769662 robustly increased phosphorylation of 
AMPK and its downstream target ACC (Fig. 1A-C) at both time points (Fig. 1E-G). 
AICAR caused a modest but statistically significant change in AMPK and ACC 
phosphorylation; however, metformin did not alter AMPK or ACC 
phosphorylation in the astrocytoma cells. Only A-769662 caused a change in 
eATP, which was increased approximately 3-fold compared to control at both 
time points (Fig. 1D-H).  Importantly, intracellular ATP was not altered by A-
769662 treatment (Fig. 1I), indicating that increased eATP is not a result of 
increased ATP supply. These data indicate that only A-769662 (at 100 μM) 
produces a large and persistent change in AMPK activity in astrocytoma cells 
causing release of ATP and increased eATP levels. 
 
A-769662 produces a concentration-dependent increase in eATP in U373 cells and 
mouse primary hypothalamic (HTAS) and cortical astrocytes (CRTAS) 
To determine whether A-769662 altered eATP levels in a concentration-
dependent manner, U373 cells and mouse primary HTAS and CRTAS cells were 
exposed to increasing concentrations of A-769662. Treatment of U373 cells with 
A-769662 for 30 minutes produced a biphasic response, with a decrease in eATP 
occurring at 25 μM, whereas concentrations greater than 50 μM increased eATP 
levels (Fig. 2A). A-769662 increased phosphorylation of AMPK and ACC in a 
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concentration-dependent manner (Fig. 2B). HTAS and CRTAS produced 
significantly less eATP at baseline, approximately 5-fold lower than U373 cells. 
However, in both cell types, A-769662 (>50 μM) increased eATP levels (Fig. 
2C,E), although the AMPK and ACC phosphorylation response to A-769662 in 
HTAS (Fig. 2D) and CRTAS (Fig. 2F) was modest compared to U373 cells. These 
data suggest that A-769662 produces comparable increases in eATP despite 
differing increases in AMPK and ACC phosphorylation. 
 
A-769662-induced increases in eATP are partially compound C-sensitive but persist 
in AMPK α1/α2 null MEFs. 
To determine whether the increase in eATP from astrocytes is mediated by 
AMPK, we pre-incubated cells in Compound C, a non-specific AMPK inhibitor (10 
μM) for 15 minutes before treatment with A-769662. We chose lower 
concentrations of A-769662 (10µM and 50µM) for these studies to limit the 
pharmacological competition between A-769662 and Compound C. In U373 cells 
and HTAS, pre-incubation with Compound C significantly attenuated the A-
769662-induced increase in eATP (Fig. 3A,B). There was a trend for reduced 
eATP in Compound C-treated cortical astrocyte (CRTAS) cells following A-
769662 treatment, which did not reach statistical significance (Fig. 3C).  
 
Given that Compound C inhibits several other molecules at or below the 
concentrations used in the present study (www.kinase-screen.mrc.ac.uk/kinase-
inhibitors), we decided to also utilise MEFs deficient for both catalytic subunits 
of AMPK (α1/α2 null) to confirm the specificity and action of A-769662. In WT 
MEFs, A-769662 (50-100 µM) induced a concentration-dependent increase in 
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eATP (up to ~4-fold following 100 µM). AMPKα1/α2 null MEFs exhibited 
significantly lower eATP levels at baseline (>80% lower); however, A-769662 
(50-100 µM) still induced an increase in eATP in these cells (Fig. 3D). When 
normalized to their respective baseline values, the fold change in eATP from 
AMPKα1/α2 null MEF cells was similar, or even enhanced at higher A-769662 
concentrations (Fig. 3E).   Similar to the U373 cells, treatment of WT or 
AMPKα1/α2 null MEF cells with AICAR or metformin for 30 minutes did not 
alter eATP levels (ESM Fig. 2A,B). Western blots confirmed that the AMPKα1/α2 
null MEF cells were deficient of catalytic subunits (ESM Fig. 2C).  To determine 
why AMPK null MEFs had significantly lower eATP, we examined the 
intracellular ATP in both WT and AMPK null MEFs. AMPK null cells had 
significantly less total ATP (~40% reduction, Fig. 3F), suggesting that, indirectly, 
AMPK contributes to maintenance of eATP levels by sustaining the intracellular 
ATP concentration. Finally, to confirm whether enhancing AMPK activity altered 
eATP, we reduced the A-769662 concentration (50 µM) to produce a comparable 
activation of AMPK to AICAR (2 mM) and co-applied both drugs to U373 cells. 
Importantly, A-769662 increased eATP levels and AMPK phosphorylation and 
when A-769662 and AICAR were applied together, AMPK phosphorylation was 
further increased by AICAR but eATP levels were not altered (Fig. 3G-I), 
indicating that AMPK is unlikely to play a role in A-769662 induced release of 
ATP. 
 
A-769662 increases intracellular calcium in U373 cells, HTAS and CRTAS 
Application of the gap junction blocker carbenoxolone did not prevent A-
769662-induced ATP release (ESM Fig. 3), we therefore tested whether ATP 
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release could be occurring through vesicular ATP release, which is dependent on 
changes in intracellular calcium ([Ca2+]i)23, 24. We performed non-ratiometric 
calcium imaging using Fluo4 Ca2+-sensitive dye. A-769662 rapidly elevated 
[Ca2+]i levels in a sustained manner (~2 minutes) in U373 (Fig. 4A), HTAS cells 
(Fig. 4B), and to a lesser extent, CRTAS cells (Fig. 4C). Intracellular [Ca2+] was 
also increased by A-769662 in the AMPKα1/α2 null MEFs although the response 
appeared more variable (not shown). We therefore performed single cell 
ratiometric calcium imaging using Fura-2. This also enabled us to examine the 
effect of A-769662 when cells were plated at low seeding density, thus limiting 
autocrine/paracrine signalling and allowing us to determine whether A-769662-
induced ATP release could activate P2 receptors to increase intracellular 
calcium. We found that in approximately 20% of AMPKα1/α2 null MEFs, A-
769662 (100 µM) induced an increase in [Ca2+]i, designated as an increase in the 
340/380 ratio of greater than 20% of baseline fluorescence (Fig. 4D,E). Isolated 
cells also demonstrated an increase in [Ca2+]i, suggesting that paracrine ATP 
signalling is unlikely to mediate the increase in [Ca2+]i and that A-769662 
increases [Ca2+]i and ATP release in a cell autonomous manner. Moreover, these 
data indicate that A-769662 does not require functional AMPK to increase [Ca2+]i 
levels. 
 
Chelation of intracellular calcium with BAPTA-AM attenuates A-769662-induced 
increases in eATP 
To determine whether the change in intracellular calcium was directly 
responsible for the increased release of ATP from astrocytes, we chelated [Ca2+]i 
using BAPTA-AM (50 μM; 30 min pre-incubation). There was a non-significant 
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trend for reduced A-769662 response in U373 cells treated with BAPTA-AM (Fig. 
4F). However, in HTAS and CRTAS, eATP levels induced by A-769662 were 
significantly lower following BAPTA-AM pre-treatment (Fig. 4G,H). Next, we pre-
exposed U373 cells, HTAS and CRTAS to a calcium-free extracellular solution to 
determine whether entry of extracellular calcium was required for ATP release. 
Under these conditions, the A-769662-induced increase in eATP was not altered 
(ESM Fig. 4A-C), although we did note a non-significant trend towards increased 
basal eATP levels in calcium-free saline in HTAS and CRTAS. Moreover, A-
769662 challenge increased intracellular calcium in U373 cells bathed in calcium 
free saline, suggesting that A-769662 induces release of calcium from 
intracellular stores (ESM Fig. 4D,E). To determine whether purinergic receptor 
activation was required for A-769662-induced ATP release, we incubated cells in 
a cocktail of P2R antagonists, PPADS, 5-BDBD and A-438079. The presence of 
these inhibitors did not prevent A-769662 from increasing eATP levels (ESM Fig. 
4F), suggesting that purinergic receptor activation is not required. Taken 
together these data suggest that release of calcium from intracellular stores 
contributes to the release of ATP induced by A-769662 by a mechanism that 
does not require purinergic receptor activation. 
 
A-769662 increases eATP levels in several endocrine cell types 
To examine whether the effect of high concentrations of A-769662 to alter ATP 
release is a general phenomenon across cell types, we performed concentration-
response studies in a variety of other central and peripheral cell types including 
mouse glucose sensing neurons (GT1-7), human neuroblastoma cells (SH-SY5Y), 
murine BV-2 microglia, rat hepatoma cells (H4IIE), mouse myoblasts (C2C12) 
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and rat pancreatic insulinoma cells (INS-1). We found that basal eATP levels 
varied across the cell types by nearly 10–fold (10-100 pmol/ml) but in every cell 
type examined, A-769662 induced a significant increase in ATP release (Fig 5A-
F). These data indicate that A-769662 also increases ATP release from other 
neural cell types namely neurons and microglia, as well as from peripheral cells 
including liver, muscle and pancreatic beta cell lines. 
 
A-769662 reduces ECAR in an AMPK-dependent and AMPK-independent manner 
AMPK is known to oppose the Warburg effect25, essentially driving energy 
production through (more efficient) oxidative phosphorylation. Therefore, to 
determine whether A-769662 altered aspects of cellular metabolism by AMPK-
dependent or AMPK-independent means, we utilised the Seahorse Extracellular 
flux analyser and exposed U373, WT MEF and AMPK α1/α2 null MEF cells to A-
769662. Over time, higher concentrations (50–100 μM) of A-769662 caused 
ECAR to decrease in U373 (ESM Fig. 5A,C), WT MEFs (ESM Fig. 5D,F) and AMPK 
α1/α2 null MEFs (ESM Fig. 5G,I). Importantly, the highest concentration of A-
769662 also reduced ECAR in AMPK null MEFs, although the magnitude of the 
response was reduced. OCR was not significantly altered in any cell type (ESM 
Fig. 5B,E,H). These data indicate that the reduction in ECAR induced by A-
769662 has AMPK-dependent and AMPK-independent components.  
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Discussion 
Astrocytes are the main source of extracellular ATP within the brain26 and given 
that AMPK acts to maintain intracellular ATP levels, we hypothesised that AMPK 
may regulate ATP release from astrocytes. We postulated that activation of 
AMPK would limit ATP release, thus maintaining the pool of ATP available for 
metabolism. In contrast, we found that the commonly used AMPK activator drug 
A-769662 produced concentration-dependent increases in eATP levels in human 
astrocytoma (U373) cells, mouse primary astrocytes and several other central 
and peripheral endocrine cell types including liver, muscle and pancreatic beta 
cells. This occurred without substantial increases in intracellular ATP suggesting 
that eATP is not increasing as a consequence of increased intracellular ATP 
availability, but due to increased release. 
 
A-769662 produced a large increase in AMPK and ACC phosphorylation in U373 
cells, with HTAS and CRTAS displaying more modest increases. A-769662 
preferentially activates AMPK heterotrimers containing the β1-subunit27, 
therefore the attenuated AMPK and ACC phosphorylation induced by A-769662 
in these cells types may reflect the relative expression (or lack thereof) of 
AMPKβ1.  AICAR at high concentrations (1-2 mM) did not alter ATP release in 
U373 cells despite a modest activation of AMPK. Importantly, we could enhance 
AMPK activation with co-treatment of U373 cells with both A-769662 and 
AICAR, however, this did not enhance eATP levels, suggesting that ATP release is 
not a consequence of AMPK activity reaching a threshold. Metformin was 
without effect on eATP or AMPK phosphorylation in U373 cells, CRTAS and MEF 
WT or MEF AMPKα1/α2 null cells, most likely due to insufficient accumulation of 
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metformin into the intracellular compartment, possibly mediated by low organic 
cation transporter 1 expression28. AMPK inhibitor Compound C significantly 
reduced A-769662-induced ATP release in U373 cells at concentrations of A-
769662 of <50 μM, however, higher concentrations of A-769662 still increased 
ATP release (not shown), suggesting that A-769662 can pharmacologically 
outcompete the effect of Compound C.  To definitively test whether A-769662-
induced ATP release was AMPK dependent, we utilised MEFs null for the AMPK 
catalytic subunits α1 and α2. In these cells, A-769662 produced a significant 
increase in eATP levels, which was not compound C-sensitive (not shown). 
Interestingly, basal eATP levels from AMPK null MEFs were >80% lower than 
WT cells, mediated by a ~40% decrease in intracellular ATP.  These data suggest 
that AMPK may contribute to eATP levels simply by maintaining intracellular 
ATP levels.  
 
Our data suggest that A-769662-induced increases in eATP are mediated by 
vesicular release, a process which is calcium-dependent23, 24, as chelation of 
intracellular calcium using BAPTA-AM, diminished eATP levels in primary 
astrocyte cultures, with a non-significant trend toward reduced release in the 
U373 cells. Removal of extracellular calcium did not alter the A-769662-induced 
ATP release, indicating that entry of extracellular calcium is not required for this 
process. We went on to investigate whether A-769662-mediated ATP release 
could activate P2 receptors via paracrine signalling, which could alter both ATP 
release (i.e. ATP-induced ATP release) or change intracellular calcium. Using 
single cell ratiometric calcium imaging, we showed that A-769662 increased 
[Ca2+]i when cells were bathed in calcium-free saline suggesting that P2X 
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receptors are not contributing to increased [Ca2+]i levels. When cells were 
present at low density with constant perfusion, a situation where 
autocrine/paracrine signalling is negligible, we found that the A-769662-induced 
increase in [Ca2+]i persisted, thus also ruling out a role for P2Y receptors. To 
determine more conclusively whether P2 receptor activation was important for 
A-769662-induced ATP release, we used a combination of a broad-spectrum P2 
receptor blocker PPADS, which has a low affinity for P2X4 and P2X729, with P2X4 
antagonist 5-BDBD and P2X7 antagonist A-438079. Under these conditions, the 
A-769662-induced ATP release from U373 cells remained. Taken together, these 
data suggest that A-769662 may increase calcium release from intracellular 
stores to induce ATP release, in a cell autonomous manner not requiring 
activation of P2Rs. 
 
There are several potential consequences of increased ATP release induced by A-
769662 that may complicate the interpretation of data utilising this drug as an 
AMPK activator in diabetes/metabolism studies. Release of ATP is a 
physiologically regulated process that occurs when cells experience a change in 
their environment. In the brain, ATP released from astrocytes is involved in 
stimulating breathing following changes in the partial pressure of CO2 30 and can 
contribute to left ventricular hypertrophy in a model of myocardial infarction in 
rats31. In muscle, eATP can enhance glucose uptake in a P2Y receptor-dependent 
mechanism, that induces GLUT4 translocation to the membrane.32 Chronically 
elevated levels of ATP have been reported to induce insulin resistance in 
cultured adipocytes33, and in blood extracellular ATP can enhance the release of 
mature IL-1β from macrophages, via a P2X7 receptor-dependent mechanism34. 
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ATP can be broken down in the extracellular space to form adenosine and recent 
evidence suggests that astrocyte-derived adenosine (released as ATP) can 
reduce food intake via activation of AgRP neuron adenosine A1 receptors18. 
Adenosine can also increase glucose uptake in mouse neurons and astrocytes via 
activation of the adenosine 2B receptor35.  
 
In conclusion, our data do not support a role for AMPK in acutely regulating ATP 
release from astrocytes. Instead, we find that complete loss of AMPK activity, 
mediated by knockout of both catalytic subunits, reduced eATP levels by 
reducing intracellular ATP levels. Moreover, A-769662 stimulated ATP release 
from cells by raising intracellular calcium levels derived from intracellular 
stores, an effect that persisted in the absence of AMPK activity and when 
purinergic receptor activation was minimised. Therefore, A-769662 promotes a 
signalling pathway(s) resulting in modified ATP release from peripheral and 
central cells, which is dependent on increased intracellular calcium. The release 
of ATP into the extracellular space caused by this drug may have an impact on 
alternative pathways including cellular glucose utilisation, inflammation and 
whole body energy metabolism, independently of AMPK activity. 
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Figure Legends 
Figure 1. A-769662 potently activates AMPK and stimulates ATP release 
from U373 cells. A. Representative immunoblots from U373 cells treated with 
A-769772 (100 μM), AICAR (1 mM) or metformin (1 mM) for 30 minutes (n=8-
9). Densitometric analysis for pT172 AMPK and pS79 ACC depicted in B and C, 
respectively. D. Analysis of extracellular ATP (eATP; n=8). E. Representative 
immunoblots from U373 cells treated with A-769662, AICAR and metformin for 
3 hours, with densitometric analysis shown for pT172 AMPK and pS79 ACC 
shown in F and G, respectively (n=8). Analysis of eATP for 3 hour treatments 
shown in H (n=8). I. Analysis of intracellular ATP (iATP) levels in U373 cells 
following 30 minutes of A-769662 treatment (n=7). *p<0.05 
 
Figure 2. A-769662 concentration-dependently increases eATP from U373 
cell and primary mouse hypothalamic and cortical astrocytes. A. Treatment 
of U373 cells with increasing concentrations of A-769662 for 30 minutes 
increases eATP (n=6), with representative immunoblots of pT172 AMPK, pS79 
ACC and actin depicted in B. C. Treatment of primary hypothalamic astrocytes 
(HTAS; n=5) with increasing concentrations of A-769662 for 30 minutes also 
increases eATP levels, with representative immunoblots depicted in D. E. 
Treatment of primary cortical astrocytes (CRTAS; n=9) with increasing 
concentrations of A-769662 for 30 minutes also increased eATP levels, with 
representative immunoblots depicted n F. *p<0.05;**p<0.01; ***p<0.001 
 
Figure 3. Compound C pre-treatment attenuates A-769662-induced 
increases in eATP but still persists in AMPK α1/α2 null mouse embryonic 
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fibroblasts (MEF). Pre-treatment of cells with Compound C (10 μM; 15 mins) 
prevented A-769662-induced increases in eATP in U373 (A; n=6) and HTAS (B; 
n=4), with a non-significant trend toward reduced release in CRTAS (C; n=5). D. 
Treatment of MEFs with A-769662 caused a concentration-dependent increase 
in eATP from WT and AMPK null MEFs. E. eATP levels from D normalised to 
baseline for each cell type. F. Intracellular ATP levels in WT versus AMPK null 
MEFs. G. Measurement of eATP following treatment of U373 cells with A-769662 
(50 μM) in the absence and presence of AICAR (2 mM; n=6). H. Representative 
immunoblots from G. I. Densitometric analysis from H.  
*p<0.05;**p<0.01;***p<0.001; $ vs vehicle; # vs WT. 
 
Figure 4. A-769662 increases intracellular calcium and chelation of 
intracellular calcium diminishes the A-769662-induced increase in eATP. 
A-C. Cells were loaded with Fluo4 direct for 60 minutes. Injection of A-769662 
(100 μM; at 0.5 min) increased the relative fluorescence (RFU) in U373 (A; n=3), 
HTAS (B; n=4) and CRTAS (C; n=4). Cells were also injected with 0.1% (v/v) 
DMSO as control (Cont). D. A representative trace of ratiometric calcium imaging 
using Fura-2 in AMPK α1/α2 null MEF cells. 340/380 ratios were normalised to 
1 to correspond with Fluo4 data. Mean relative fluorescence units from a field of 
9 AMPK α1/α2 null MEF cells. E. Representative images of ratiometric calcium 
signals before and after A-769662 treatment in AMPK α1/α2 null MEF cells. F. 
Pre-incubation of cells with BAPTA-AM (50 μM) for 30 minutes prior to A-
769662 addition did not significantly alter eATP levels from U373 cells (n=8). 
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BAPTA-AM pre-treatment significantly reduced A-769662-induced eATP levels 
in HTAS (G; n=5) and CRTAS (H; n=6). *p<0.05; **p<0.01;***p<0.001 
 
Figure 5. A-769662 increases eATP in a number of other endocrine cells. A-
769662 increased eATP levels from mouse glucosensing hypothalamic GT1-7 
neurons (A; n=5), human Sh-SY5Y neuroblastoma cells (B; n=6), murine BV-2 
microglia (C; n=7), rat hepatoma H4IIE cells (D; n=6), mouse C2C12 myoblasts 
(E; n=9) and rat pancreatic beta cell INS-1E cells (F; n=4). *p<0.05; 
**p<0.01;***p<0.001 
 
ESM Figure 1. Validation of mouse primary astrocyte cultures. Top row: 
Primary cortical astrocyte (CRTAS) stained with DAPI (nuclear stain), glial 
fibrillary acidic protein (GFAP) and Iba1 (microglial marker). CRTAS cultures 
had >80% GFAP positive cells and <2% Iba1-positive cells. Bottom row: Primary 
hypothalamic astrocyte (HTAS) cultures stained with DAPI, GFAP and Iba1. HTAS 
cultures had >85% GFAP-positive cells and <2% Iba1-positive cells. 
 
ESM Figure 2. Metformin and AICAR do not alter eATP levels in MEF WT or 
MEF AMPK α1/α2 null cells. A. Analysis of extracellular ATP (eATP) from wild 
type mouse embryonic fibroblasts (MEF WT) treated with A-769662 (100 μM), 
AICAR (1 mM) or metformin (1 mM) for 30 minutes (n=5). B. Analysis of eATP 
from MEF AMPKα1/α2 null cells following treatment with A-769662, AICAR and 
metformin, as above (n=5). C. Representative immunoblot of MEF WT and AMPK 
α1/α2 null cells treated with A-769662 (100 μM), AICAR (1 mM) and metformin 
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(1 mM) for 30 minutes and probed for pT172 AMPK and actin (n=3). **p<0.01; 
***p<0.001 
 
ESM Figure 3. Gap junction blockade with carbenoxolone did not prevent A-
769662-induced increases in eATP. A. Pre-treatment of U373 cells with 
carbenoxolone (100 μM) significantly enhanced A-769662 (100 μM)-induced 
eATP levels (n=3). Pre-treatment of HTAS (B; n=4) and CRTAS (C; n=5) with 
carbenoxlone did not significantly alter A-769662-induced increases in eATP 
levels. *p<0.05;**p<0.01 
 
ESM Figure 4. Incubation in calcium free saline did not prevent A-769662-
induced increases in eATP or intracellular calcium and pharmacological 
blockage of purinergic receptors does not prevent A-769662-induced ATP 
release. Incubation of U373 cells (A; n=5), primary hypothalamic astrocytes 
(HTAS; B; n=8) or primary mouse cortical astrocytes (CRTAS; C; n=6) in an 
extracellular saline solution containing zero calcium did not attenuate the A-
769662 (100 μM) induced increase in eATP. D. Representative ratiometric 
calcium imaging trace (one of 3 independent experiments) of U373 cells treated 
with A-769662 (100 μM) in calcium free saline (mean normalised relative 
fluorescence units of 29 cells). E. Representative images pre and post addition of 
A-769662. F. Analysis of eATP levels from U373 cells treated with A-769662 plus 
a cocktail of purinergic receptor antagonists (PPADS [100 μm]; 5-BDBD [5 μM]; 
A-438069 [100 μM]. *p<0.05;**p<0.01 
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Figure ESM 5. A-769662 decreases the extracellular acidification rate with 
AMPK-dependent and AMPK-independent components. A. Extracellular 
acidification rate (ECAR) normalised to baseline of U373 cells exposed to A-
769662. B. Oxygen consumption rate (OCR) of U373 cells exposed to A-769662, 
normalised to baseline. C. Extrapolation of ECAR data approximately 90 mins 
post injection. D. ECAR normalised to baseline of WT MEF cells exposed to A-
769662. E. Oxygen consumption rate (OCR) of WT MEF cells exposed to A-
769662, normalised to baseline. F. Extrapolation of ECAR data approximately 90 
mins post injection (n=14-16). G. ECAR normalised to baseline of AMPK α1/α2 
null MEF cells exposed to A-769662. H. Oxygen consumption rate (OCR) of AMPK 
α1/α2 null MEF cells exposed to A-769662, normalised to baseline. I. 
Extrapolation of ECAR data approximately 90 minutes post injection. 
*p<0.05;**p<0.01;***p<0.001; n=14-16. 
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Figure 1. A-769662 potently activates AMPK and stimulates ATP release from U373 cells. A.
Representative immunoblots from U373 cells treated with A-769662 (100 μM), AICAR (1 mM) or metformin (1
mM) for 30 minutes (n=8-9).  Densitometric analysis for pT172 AMPK and pS79 ACC depicted in B and C,
respectively. D. Analysis of extracellular ATP (eATP; n=8). E. Representative immunoblots from U373 cells
treated with A-769662, AICAR and metformin for 3 hours, with densitometric analysis shown for pT172 AMPK
and pS79 ACC shown in F and G, respectively (n=8). Analysis of eATP for 3 hours treatments shown in H (n=8).
I. Analysis of intracellular ATP(iATP) levels in U373 cells following 30 minutes of A-769662 treatment (n=7). 
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Figure 2.  A-769662 concentration-dependently increases eATP from U373 cells and
primary mouse hypothalamic and cortical astrocytes. A. Treatment of U373 cells with
increasing concentrations of A-769662 for 30 minutes increases eATP (n=6), with
representative immunoblots of pT172 AMPK, pS79 ACC and actin depicted in B. C. Treatment
of primary hypothalamic astrocytes (HTAS; n=5) with increasing concentrations of A-769662
for 30 minutes also increases eATP levels, with representative immunoblots depicted in D. E.
Treatment of primary cortical astrocytes (CRTAS; n=9) with increasing concentrations of
A-769662 for 30 minutes also increased eATP levels, with representative immunoblots
depicted in F. p*<0.05; **p<0.01; ***p<0.001
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Figure 3. Compound C pre-treatment attenuates A-769662-induced increases in eATP but still persists
in AMPK α1/α2 null mouse embryonic fibroblasts (MEF). Pre-treatment of cells with Compound C (10 μM;
15 mins) prevented A-769662-induced increases in eATP in U373 (A; n=6) and HTAS (B; n=4), with a non-
significant trend toward reduced release in CRTAS (C; n=5). D. Treatment of MEFs with A-769662 caused a
concentration-dependent increase in eATP from WT and AMPK null MEFs. E. eATP levels from D normalised
to baseline for each cell type. F.  Intracellular ATP levels in WT versus AMPK null MEFs. G. Measurement of
eATP following treatment of U373 cells with A-769662 (100 μM) in the absence and presence of AICAR (2
mM; n=6). H. Representative immunoblots from G. I. Densitometric analysis from H.
*p<0.05;**p<0.01;***p<0.001; $ vs vehicle; # vs WT. 
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Figure 4. A-769662 increases intracellular calcium and chelation of intracellular calcium diminishes 
the A-769662-induced increase in eATP. A-C. Cells were loaded with Fluo4 direct for 60 minutes. 
Injection of A-769662 (100 μM; at 0.5 min) increased relative fluorescence (RFU) in U373 (A; n=3), HTAS 
(B; n=4) and CRTAS (C; n=4). Cells were also injected with 0.1% (v/v) DMSO as control (Cont). D. A 
representative  trace of ratiometric calcium imaging using Fura-2 in AMPK α1/α2 null MEF cells. 340/380 
ratios were normalised to 1 to correspond with Fluo4 data. Mean relative fluorescence units from a field of 9 
AMPK KO MEF cells. E. Representative images of ratiometric calcium signals before and after A-769662 
treatment in AMPK α1/α2 null MEF cells.  F. Preincubation of cells with BAPTA-AM (50 μM) for 30 minutes 
prior to A-769662 addition did not significantly alter eATP levels from U373 cells (n=8). BAPTA-AM pre-
treatment significantly reduced A-769662-induced eATP levels in HTAS (G; n=5) and CRTAS (H; n=6). 
*p<0.05;**p<0.01; ***p<0.001  
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Figure 5. A-769662 increases eATP in a number of other endocrine cells. A-769662
increased eATP levels from mouse glucosensing hypothalamic GT1-7 neurons (A; n=5), human
SH-SY5Y neuroblastoma cells (B; n=6), murine BV-2 microglia (C; n=7), rat hepatoma H4IIE cells
(D; n=6), mouse C2C12 muscle myoblasts (E; n=9) and rat pancreatic beta cell INS-1 cells (F;
n=4) *p<0.05;**p<0.01;***p<0.001
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